Rapamycin in mice and humans: lifespan, immune effects and trial limits
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description says rapamycin extends lifespan in mice, even when started late in life, and is now tested in humans; the PEARL trial showed mixed results, and the evidence is not sufficient to recommend rapamycin for general longevity use. [1]
The description says rapamycin inhibits mTOR, a central nutrient-sensing pathway regulating cell growth, autophagy and protein synthesis, and that caloric restriction, fasting and rapamycin converge on the same pathway. [1]
The description reports that rapamycin extends lifespan in mice, even when started late in life. [1]
The description says the PEARL trial's results were mixed, with signals for improved immune function and reduced infections but also concerns about insulin resistance and immune suppression, and that evidence is not yet sufficient to recommend rapamycin for general longevity use. [1]
mTOR inhibition and how it is measured
The description says rapamycin inhibits mTOR, described as a central nutrient-sensing pathway regulating cell growth, autophagy and protein synthesis. It adds that caloric restriction, fasting and rapamycin converge on the same pathway. In humans, mTOR inhibition is measured through downstream markers such as p70S6K phosphorylation, autophagy flux and immune cell function; the description states there is no simple blood test for "mTOR activity." [1]
Mouse lifespan and mixed PEARL trial signals
The description reports that rapamycin extends lifespan in mice, even when started late in life. It names the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) as one of the first randomized human trials and says results were mixed: signals for improved immune function and reduced infections, but also concerns about insulin resistance and immune suppression. The description states the evidence is not yet sufficient to recommend rapamycin for general longevity use. [1]
Transplant dosing versus longevity dosing and missing safety data
The description says transplant medicine has used rapamycin for decades as an immunosuppressant, and that longevity dosing (intermittent, low-dose) is fundamentally different from transplant dosing (daily, high-dose). It names the absence of long-term human safety data as the main reason most clinicians hesitate, and notes that rapamycin is a prescription drug with serious potential side effects. [1]
Context & limits
This is based only on the video description; the video and transcript were not reviewed. The description gives no sample sizes, follow-up durations or effect sizes, and the mouse and human findings are reported only in summary form.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
rapamycin inhibits mTOR (mechanistic target of rapamycin)
Rapamycin extends lifespan in mice, even when
results have been mixed
About this video
Creator description · original textText language: English
itinai · 26 min · Source published: 2026-10-15
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.